20 YEARS OF PROFESSIONAL & DEDICATED SERVICE TO GLOBAL CUSTOMERS

Custom Manufacturing, Project Outsourcing, your Trusted Partner from China

Clinical Efficacy of Capmatinib: Results from the GEOMETRY Mono-1 Trial

NINGBO INNO PHARMCHEM CO.,LTD. recognizes the critical importance of robust clinical data in the pharmaceutical landscape. For targeted therapies like Capmatinib Hydrochloride, understanding the clinical efficacy is paramount for both healthcare professionals and the industry.

The cornerstone of evidence supporting Capmatinib Hydrochloride's use in treating Non-Small Cell Lung Cancer (NSCLC) with MET exon 14 skipping mutations is the GEOMETRY mono-1 trial. This pivotal phase II study was instrumental in demonstrating the drug's effectiveness and securing its regulatory approvals.

The GEOMETRY mono-1 trial was a multicenter, non-randomized, open-label study that enrolled patients with advanced or metastatic NSCLC, specifically those with confirmed MET exon 14 skipping mutations. The study evaluated the efficacy of Capmatinib Hydrochloride at a dose of 400 mg orally twice daily. Patients were treated until disease progression or unacceptable toxicity.

Key efficacy endpoints measured in the trial included the overall response rate (ORR), which is the percentage of patients who experienced a significant reduction in tumor size, and the duration of response (DOR). The results were highly encouraging:

  • Treatment-Naïve Patients: In the cohort of patients who had not received prior systemic therapy for their metastatic disease, Capmatinib Hydrochloride demonstrated an overall response rate of 68%.
  • Previously Treated Patients: For patients who had received at least one prior line of therapy, the ORR was 41%.
  • Duration of Response: The median duration of response was approximately 12.6 months for treatment-naïve patients and 9.7 months for previously treated patients, indicating sustained clinical benefit for many individuals.

These findings highlight the substantial impact Capmatinib Hydrochloride can have on patients with this specific genetic profile in NSCLC. The trial's success paved the way for its approval by regulatory agencies, positioning it as a vital therapeutic option.

At NINGBO INNO PHARMCHEM CO.,LTD., we provide the high-quality Capmatinib Hydrochloride required for such critical clinical applications. When exploring options to purchase Capmatinib Hydrochloride, understanding the data from trials like GEOMETRY mono-1 underscores its value and therapeutic potential. Our commitment to quality ensures that the APIs we supply are of the highest standard, supporting the development and availability of advanced cancer treatments.

Manufacturing Facilities

NINGBO INNO PHARMCHEM CO.,LTD. was established in 2007. It is committed to the R&D, production and sales of raw materials, pharmaceutical intermediates and fine chemicals. We striving to create a high-efficiency and high-quality integrated chemical service platform to better serve domestic and foreign customers.

Professional Export Experience

to Global Customers

WHY CHOSE US?

1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;

2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;

3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).

FAQ

  • A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.

  • A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.

  • A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.

CONTACT US
Should you need to contact us; you may call during regular business hours, Monday through Friday, 8am – 6 pm.
NINGBO INNO PHARMCHEM CO.,LTD.
Address: No.163 Ruiqing Rd.,Ningbo 315000 China
Phone: 86-574-87319282
Fax: 86-574-27912196
SEND US AN EMAIL

NAME*

EMAIL*

COMPANY

COUNTRY*

MESSAGE*

Previous: The Science Behind Capmatinib: Targeting MET in Lung Cancer

Next: Safety and Adverse Effects of Capmatinib Hydrochloride in Cancer Therapy

All Rights Reserved